Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines

Table 1 IC ₅₀ of each cytotoxic agent alone and in combination with dasatinib (IC ₂₅ ) and coefficient of drug interaction (CDI)

Cell Line	Drugs	IC ₅₀	CDI
SK-UT-1
	Gemcitabine	4.02 (SD ± 1.0)
	Docetaxel	4.30 (SD ± 0.5)
	Gemcitabine:Dasatinib IC₂₅	2.35 (SD ± 1.4)	0.72
	Docetaxel:Dasatinib IC₂₅	1.15 (SD ± 0.07)	0.80
SK-UT-1B
	Gemcitabine	2.97 (SD ± 0.5)
	Docetaxel	0.94 (SD ± 0.6)
	Gemcitabine:Dasatinib IC₂₅	0.85 (SD ± 0.6)	0.83
	Docetaxel:Dasatinib IC₂₅	0.52 (SD ± 0.4)	0.93

SD = standard deviation.
IC₅₀ = 50% of maximal inhibitory concentration.
IC₂₅ = 25% of maximal inhibitory concentration.
CDI = Coefficient of drug interaction. Calculation utilize when one drug does not achieve an IC_50.
CDI scale = CDI < 1 indicates synergism between dasatinib and cytotoxic agents, whereas CDI < 0.7 indicates significant synergism.

ISSN: 2053-6844